Facilitating Drug Discovery With Induced Pluripotent Stem Cells

Download Axol’s free white paper - "Induced Pluripotent Stem Cells: recapitulating disease to facilitate drug discovery"

Understand more about how iPSC-derived cells can improve any drug development research program by supplying a physiologically relevant model, which is capable of representing a disease population. This enables research in multiple stages of the development pipeline.

Using iPSC-Derived Cells for Target Identification

This white paper comprises cases wherein iPSC-derived cells have been utilized for target identification, target validation, lead optimization and safety testing, as a means of reducing failure rates of drug candidates.

Download Axol’s white paper and find out how hiPSCs are an essential tool in drug discovery.

About AXOL Biosciences

Axol specializes in human cell culture.

Axol produces high quality human cell products and critical reagents such as media and growth supplements. We have a passion for great science, delivering epic support and innovating future products to help our customers advance faster in their research.

Our expertise includes reprogramming cells to iPSCs and then differentiating to various cell types. We supply differentiated cells derived from healthy donors and patients of specific disease backgrounds. As a service, we also take cells provided by customers (primary or iPSC) and then do the reprogramming (when necessary) and differentiation. Clearly, by offloading the burden of generating cells, your time is freed up to focus on the research. Axol holds the necessary licenses that are required to do iPSC work.

The package wouldn't be complete without optimized media, coating solutions and other reagents. Our in-house R&D team works hard to improve on existing media and reagents as well as innovate new products for human cell culture. We also supply a growing range of human primary cells; making Axol your first port of call for your human cell culture needs.

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Feb 18, 2020 at 11:34 AM


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Axol Bioscience Ltd. (2020, February 18). Facilitating Drug Discovery With Induced Pluripotent Stem Cells. News-Medical. Retrieved on April 06, 2020 from https://www.news-medical.net/whitepaper/20200106/Facilitating-Drug-Discovery-With-Induced-Pluripotent-Stem-Cells.aspx.

  • MLA

    Axol Bioscience Ltd. "Facilitating Drug Discovery With Induced Pluripotent Stem Cells". News-Medical. 06 April 2020. <https://www.news-medical.net/whitepaper/20200106/Facilitating-Drug-Discovery-With-Induced-Pluripotent-Stem-Cells.aspx>.

  • Chicago

    Axol Bioscience Ltd. "Facilitating Drug Discovery With Induced Pluripotent Stem Cells". News-Medical. https://www.news-medical.net/whitepaper/20200106/Facilitating-Drug-Discovery-With-Induced-Pluripotent-Stem-Cells.aspx. (accessed April 06, 2020).

  • Harvard

    Axol Bioscience Ltd. 2020. Facilitating Drug Discovery With Induced Pluripotent Stem Cells. News-Medical, viewed 06 April 2020, https://www.news-medical.net/whitepaper/20200106/Facilitating-Drug-Discovery-With-Induced-Pluripotent-Stem-Cells.aspx.

Other White Papers by this Supplier